T. Rowe Price Investment Management, Inc. Atai Life Sciences N.V. Transaction History
T. Rowe Price Investment Management, Inc.
- $164 Billion
- Q3 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 1,939,951 shares of ATAI stock, worth $7.76 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,939,951Holding current value
$7.76 Million% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding ATAI
# of Institutions
141Shares Held
38.9MCall Options Held
1.74MPut Options Held
525K-
Ubs Group Ag7.68MShares$30.7 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.43MShares$21.7 Million0.05% of portfolio
-
Morgan Stanley New York, NY4.82MShares$19.3 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.58MShares$10.3 Million0.0% of portfolio
-
Ally Bridge Group (Ny) LLC New York, NY2.29MShares$9.15 Million12.47% of portfolio
About ATAI Life Sciences N.V.
- Ticker ATAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 165,875,008
- Market Cap $664M
- Description
- Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...